The study will analyse electronic health records of 65- and 66-year olds from the UK’s National Health Service (NHS).

The British pharmaceutical giant is working with the U.K. Dementia Research Institute to exploit a “natural randomization” ...

After multiple studies have suggested a link between its shingles vaccine and dementia prevention, GSK is taking advantage of ...

Prominent outside scientists who help the NIH evaluate its internal research programs are being abruptly removed ...

GSK said on Tuesday that it is studying a group of more than a million older adults in the UK to examine whether its ...

GSK, led by boss Emma Walmsley (pictured), is using the data of 1.4m adults aged 65 and 66 to examine the impact of its ...

UK pharma major GSK (LSE: GSK) today announced a major new research collaboration with the UK Dementia Research Institute (UK ...

GSK partners with UK research groups to study if Shingrix shingles vaccine reduces dementia risk, analyzing NHS data from ...

To test it prospectively, GSK will work with the UK Dementia Research Institute (UK DRI) and Health Data Research UK (HDR UK) ...

In its effort to rival GSK’s shingles vaccine Shingrix, Curevo Vaccine has circled up $110 million and recruited two former ...

GSK Plc is studying a large group of elderly adults in the UK to determine if its blockbuster shingles vaccine reduces the risk of dementia, potentially opening the door to an expanded label for the ...

At present, Shingrix is used to prevent herpes zoster (shingles), a painful skin rash caused by the varicella-zoster virus.